Condensed Consolidated Statements of Stockholders’ Deficit - USD ($)	Series A Preferred Stock	Class A Common Stock	Class B Common Stock	Additional Paid-in- Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interests	Total
Balance at Dec. 31, 2020				$ 142,346,852	$ (87,300,472)	$ (48,539)	$ 11,949,200	$ 66,947,041
Balance (in Shares) at Dec. 31, 2020	28,055	35,497	55,008
Effect of reverse acquisition
Effect of reverse acquisition (in Shares)	18,099,548	22,900,719	35,488,938
Conversion of share due to merger recapitalization		$ 7,649						7,649
Conversion of share due to merger recapitalization (in Shares)	(18,099,548)	(22,900,719)	(35,488,938)
Effect of reverse acquisition		$ 7,649		142,346,852	(87,300,472)	(48,539)	11,949,200	66,954,690
Effect of reverse acquisition (in Shares)		76,489,205
Share issued for services		$ 17						17
Share issued for services (in Shares)	266	171,608
Stock based compensation				391,534				391,534
Noncontrolling interest contribution							333,025	333,025
Foreign currency translation						7,998		7,998
Net income (loss) attributable to Noncontrolling interests							(320,632)	(320,632)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					(1,678,364)			(1,678,364)
Balance at Mar. 31, 2021		$ 7,666		142,738,386	(88,978,836)	(40,541)	11,961,593	65,688,268
Balance (in Shares) at Mar. 31, 2021	28,321	76,660,813
Balance at Dec. 31, 2020				142,346,852	(87,300,472)	(48,539)	11,949,200	66,947,041
Balance (in Shares) at Dec. 31, 2020	28,055	35,497	55,008
Acquisitions								271,194
Balance at Sep. 30, 2021		$ 7,666		143,289,262	(87,117,532)	123,307	10,760,917	67,063,620
Balance (in Shares) at Sep. 30, 2021	28,321	76,660,813
Balance at Mar. 31, 2021		$ 7,666		142,738,386	(88,978,836)	(40,541)	11,961,593	65,688,268
Balance (in Shares) at Mar. 31, 2021	28,321	76,660,813
Stock based compensation				370,000				370,000
Foreign currency translation						94,655		94,655
Net income (loss) attributable to Noncontrolling interests							1,748,223	1,748,223
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					(1,646,216)			(1,646,216)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries (in Shares)
Balance at Jun. 30, 2021		$ 7,666		143,108,386	(90,625,052)	54,114	13,709,816	66,254,930
Balance (in Shares) at Jun. 30, 2021	28,321	76,660,813
Stock based compensation				463,046				463,046
UK Ltd. Shares purchase				(280,772)			(242,945)	(523,717)
UK Ltd. Shares purchase (in Shares)
Fees associated with equity raise				(1,398)				(1,398)
Net income attributable to stockholders of Ambulnz, Inc. and Subsidiaries					3,507,520			3,507,520
Foreign currency translation						69,193		69,193
Net income (loss) attributable to Noncontrolling interests							(2,705,954)	(2,705,954)
Balance at Sep. 30, 2021		$ 7,666		143,289,262	(87,117,532)	123,307	10,760,917	67,063,620
Balance (in Shares) at Sep. 30, 2021	28,321	76,660,813
Balance at Dec. 31, 2021		$ 10,013		283,161,216	(63,556,714)	(32,501)	7,475,010	227,057,024
Balance (in Shares) at Dec. 31, 2021		100,133,953
Exercise of stock options		$ 195		374,149				374,344
Exercise of stock options (in Shares)		195,152
Stock based compensation				1,422,937				1,422,937
Equity cost				(19,570)				(19,570)
Noncontrolling interest contribution							2,063,000	2,063,000
Foreign currency translation						(5,863)		(5,863)
Net income (loss) attributable to Noncontrolling interests							(1,257,257)	(1,257,257)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					10,629,694			10,629,694
Balance at Mar. 31, 2022		$ 10,208		284,938,732	(52,927,020)	(38,364)	8,280,753	240,264,309
Balance (in Shares) at Mar. 31, 2022		100,329,105
Balance at Dec. 31, 2021		$ 10,013		283,161,216	(63,556,714)	(32,501)	7,475,010	$ 227,057,024
Balance (in Shares) at Dec. 31, 2021		100,133,953
Cashless exercise of options (in Shares)								1,637,159
Acquisitions								$ 819,231
Balance at Sep. 30, 2022		$ 10,778		301,522,213	(37,036,937)	(276,213)	6,613,018	270,832,859
Balance (in Shares) at Sep. 30, 2022		102,824,878
Balance at Mar. 31, 2022		$ 10,208		284,938,732	(52,927,020)	(38,364)	8,280,753	240,264,309
Balance (in Shares) at Mar. 31, 2022		100,329,105
Common stock repurchased		$ (70)		(497,829)				(497,899)
Common stock repurchased (in Shares)		(70,000)
UK Ltd. Restricted Stock		$ 8		82,297				82,305
UK Ltd. Restricted Stock (in Shares)		8,258
Exercise of stock options		$ 418		778,648				779,066
Exercise of stock options (in Shares)		417,927
Stock based compensation				1,999,619				1,999,619
Foreign currency translation						10,434		10,434
Net income (loss) attributable to Noncontrolling interests							(979,791)	(979,791)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					12,735,653			12,735,653
Balance at Jun. 30, 2022		$ 10,564		287,301,467	(40,191,367)	(27,930)	7,300,962	254,393,696
Balance (in Shares) at Jun. 30, 2022		100,685,290
Common stock repurchased
Cashless exercise of options		$ 35		(354)				(319)
Cashless exercise of options (in Shares)		354,276
UK Ltd. Restricted Stock				95,543				95,543
Share warrants conversion		$ 141		12,381,432				12,381,573
Share warrants conversion (in Shares)		1,406,371
Acquisitions
Exercise of stock options		$ 38		728,465				728,503
Exercise of stock options (in Shares)		378,941
Stock based compensation				1,015,660				1,015,660
Foreign currency translation						(248,283)		(248,283)
Net income (loss) attributable to Noncontrolling interests							(687,944)	(687,944)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					3,154,430			3,154,430
Balance at Sep. 30, 2022		$ 10,778		$ 301,522,213	$ (37,036,937)	$ (276,213)	$ 6,613,018	$ 270,832,859
Balance (in Shares) at Sep. 30, 2022		102,824,878